Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
暂无分享,去创建一个
N. Mackman | N. Key | R. Kasthuri | H. Liebman | David A Manly | D. Manly | Jianguo Wang | Sam L. Glover
[1] O. Wagner,et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Bertina,et al. Microparticle‐associated tissue factor activity in cancer patients with and without thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[3] J. Freyssinet,et al. Circulating procoagulant microparticles in patients with venous thromboembolism. , 2009, Thrombosis research.
[4] A. Khorana,et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.
[5] C. Marosi,et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). , 2007, Blood.
[6] N. Mackman,et al. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[7] A. Khorana,et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.
[8] K. Aonuma,et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer , 2007, British Journal of Cancer.
[9] S. Eichinger,et al. Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer , 2006, Thrombosis and Haemostasis.
[10] R. Bertina,et al. Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? , 2007, Journal of thrombosis and haemostasis : JTH.
[11] H. Chew,et al. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? , 2007, Thrombosis research.
[12] J. Freyssinet,et al. Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[13] S Seeber,et al. Risk factors for venous thromboembolic events in cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] L. Horstman,et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. , 2005, Journal of the American College of Cardiology.
[15] B. Cosmi,et al. The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. , 2005, Haematologica.
[16] G. Escolar,et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. , 2004, Blood.
[17] R. Hebbel,et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. , 2003, Blood.
[18] Y. Nemerson,et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.